COVID-19 and financial toxicity in patients with renal cell carcinoma.

ABSTRACT:

Purpose

To ascertain renal cell carcinoma (RCC) financial toxicity on COVID-19 during the COVID-19 crisis as patients are struggling with therapeutic and financial implications.

Methods

An online survey was conducted from March 22 to March 25, 2020. It included baseline demographic, clinicopathologic, treatment-related information, anxiety levels related to COVID-19, questions related to financial concerns about COVID-19 as well as the validated 11-item COST measure.

Results

Five-hundred-and-thirty-nine patients (39%:58% male:female) from 14 countries responded. 23% of the patients did not feel in control of their financial situation but 8% reported being very satisfied with their finances. The median COST score was 21.5 (range 1-44). Metastatic patients who have not

SUBMITTER: Staehler MD 

PROVIDER: S-EPMC7578440 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature